Subsequent studies with higher number of patients in each group (SCC and AC) and subgroups (T1 and ≥T2) should provide conclusive information correlating CCR9 expression in NSCLC with disease progression and survival. The gene discussed is CCR9; the disease is non-small cell lung carcinoma.